[go: up one dir, main page]

PE20210417A1 - Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende - Google Patents

Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende

Info

Publication number
PE20210417A1
PE20210417A1 PE2021000205A PE2021000205A PE20210417A1 PE 20210417 A1 PE20210417 A1 PE 20210417A1 PE 2021000205 A PE2021000205 A PE 2021000205A PE 2021000205 A PE2021000205 A PE 2021000205A PE 20210417 A1 PE20210417 A1 PE 20210417A1
Authority
PE
Peru
Prior art keywords
amino
pharmaceutical composition
morpholinomethyl
methylthiazol
pyridin
Prior art date
Application number
PE2021000205A
Other languages
English (en)
Inventor
Wol-Young Kim
Yeon Im Lee
Youn Jung Yoon
Joon Seok Park
Deok Ki Eom
Keuk-Chan Bang
Jaehyun Jung
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Priority claimed from PCT/KR2019/010894 external-priority patent/WO2020045941A1/ko
Publication of PE20210417A1 publication Critical patent/PE20210417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un compuesto de formula quimica 1, o una sal farmaceuticamente aceptable del mismo, donde: B es un heterociclo de 5 o 6 miembros que contiene 1 a 3 heteroatomos seleccionados independientemente de N, O y S, siempre que el heterociclo incluya al menos un N; R1 es hidrogeno, halogeno, entre otros; X1 y X2 son N o CR'; R' es hidrogeno o halogeno; L es un enlace, alquileno C1-4 u O; R2 es ciano, alquilo C1-4, arilo C6-10, entre otros; Y es un enlace, -O-, entre otros; A es aqluilo C1-4, entre otros. Son compuestos especificos: 1-(3-((6-((5-metiltiazol-2-il)amino)-4-(morfolinometil)piridin-2-il)amino)piperidin-1-il)prop-2-en-1-ona; 1-(3-((6-((5-metiltiazol-2-il)amino)-4-(morfolinometil)piridin-2-il)amino)pirrolidin-1-il)prop-2-en-1-ona; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos derivados de amina heterociclica son inhibidores de la tirosina quinasa de Bruton (BTK), siendo utiles en el tratamiento o prevencion de enfermedades autoinmunitarias o cancer.
PE2021000205A 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende PE20210417A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180100359 2018-08-27
KR1020190104641A KR102328682B1 (ko) 2018-08-27 2019-08-26 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
PCT/KR2019/010894 WO2020045941A1 (ko) 2018-08-27 2019-08-27 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
PE20210417A1 true PE20210417A1 (es) 2021-03-04

Family

ID=69802542

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000205A PE20210417A1 (es) 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende
PE2025001198A PE20251890A1 (es) 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2025001198A PE20251890A1 (es) 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende

Country Status (21)

Country Link
US (1) US12227498B2 (es)
EP (2) EP4643954A2 (es)
JP (1) JP7162741B2 (es)
KR (1) KR102328682B1 (es)
CN (1) CN112638910B (es)
AU (1) AU2019331328B2 (es)
BR (2) BR112021003652B1 (es)
CA (1) CA3108856C (es)
CL (1) CL2021000421A1 (es)
CO (1) CO2021001849A2 (es)
DO (1) DOP2021000030A (es)
EC (1) ECSP21011232A (es)
MA (1) MA53507A (es)
MX (1) MX2021002188A (es)
MY (1) MY205156A (es)
PE (2) PE20210417A1 (es)
PH (1) PH12021550329A1 (es)
RU (1) RU2760184C1 (es)
SA (1) SA521421262B1 (es)
SG (1) SG11202101451QA (es)
TN (1) TN2021000025A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US20220288069A1 (en) * 2019-07-19 2022-09-15 Bridgene Biosciences, Inc. Inhibitors of tyrosine kinase
EP4112617A4 (en) * 2020-02-26 2024-03-13 Daewoong Pharmaceutical Co., Ltd. PROCESS FOR PREPARING HETEROCYCLIC AMINE DERIVATIVES
KR20210124569A (ko) * 2020-04-03 2021-10-15 주식회사 하임바이오 암 치료를 위한 신규 화합물 및 이를 포함하는 조성물
CN114605404B (zh) * 2022-03-23 2024-01-05 合肥美诺医药有限公司 一种新型含噻唑类化合物、中间体及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DE3905763A1 (de) * 1989-02-24 1990-09-06 Bayer Ag Sulfonylierte azinyliminoheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide
CN1390215A (zh) 1999-09-10 2003-01-08 麦克公司 酪氨酸激酶抑制剂
DK1103545T3 (da) 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005056785A2 (en) 2003-12-05 2005-06-23 Vertex Pharmaceuticals, Inc. Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof
US20070032403A1 (en) 2003-12-30 2007-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the ITK kinase domain
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8002915B2 (en) 2006-09-30 2011-08-23 Tk Holdings, Inc. Gas generant compositions
AU2008279097B2 (en) 2007-07-25 2013-05-02 Bristol-Myers Squibb Company Triazine kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2440052A4 (en) 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
CN102625708A (zh) 2009-09-09 2012-08-01 阿维拉制药公司 Pi3激酶抑制剂及其用途
NZ620174A (en) * 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US8759366B2 (en) 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
KR20180117731A (ko) 2010-10-15 2018-10-29 스와겔로크 컴패니 페룰을 갖는 푸시 접속 도관 피팅
KR101682417B1 (ko) 2011-02-25 2016-12-06 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
UA117451C2 (uk) 2012-01-06 2018-08-10 Аджиос Фармасьютікалз, Інк. Терапевтично активні сполуки і способи їх застосування
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
WO2014055934A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
KR20160002850A (ko) * 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
DK2994465T3 (en) 2013-05-10 2018-10-08 Karus Therapeutics Ltd HISTONDEACETYLASE INHIBITORS UNKNOWN
WO2015025197A1 (en) 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
EP3060550B1 (en) 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
CN104628657A (zh) 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2016001341A1 (en) 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
AU2015335788B2 (en) 2014-10-22 2020-07-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2016105582A1 (en) 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
WO2016177347A1 (en) 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
KR102686957B1 (ko) 2016-11-08 2024-07-22 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
ES2922633T3 (es) 2017-12-28 2022-09-19 Daewoong Pharmaceutical Co Ltd Derivado de oxi-fluoropiperidina como inhibidor de cinasa
WO2020045941A1 (ko) 2018-08-27 2020-03-05 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US12098117B2 (en) 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
EP3898614A1 (en) 2018-12-17 2021-10-27 Tolremo Therapeutics AG Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
EP4112617A4 (en) 2020-02-26 2024-03-13 Daewoong Pharmaceutical Co., Ltd. PROCESS FOR PREPARING HETEROCYCLIC AMINE DERIVATIVES
WO2022071772A1 (ko) 2020-09-29 2022-04-07 (주)메디톡스 단백질 키나제 저해제 및 그의 용도
WO2022199599A1 (zh) 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
US20220064155A1 (en) 2022-03-03
CO2021001849A2 (es) 2021-02-26
BR112021003652A2 (pt) 2021-05-18
CN112638910B (zh) 2024-06-11
TN2021000025A1 (en) 2022-10-03
ECSP21011232A (es) 2021-03-31
SG11202101451QA (en) 2021-03-30
EP3845530A1 (en) 2021-07-07
MX2021002188A (es) 2021-05-14
EP4643954A2 (en) 2025-11-05
KR102328682B1 (ko) 2021-11-18
CN112638910A (zh) 2021-04-09
AU2019331328B2 (en) 2022-03-17
MY205156A (en) 2024-10-04
JP2021534256A (ja) 2021-12-09
EP3845530A4 (en) 2022-04-27
JP7162741B2 (ja) 2022-10-28
CL2021000421A1 (es) 2021-07-23
BR112021003652B1 (pt) 2022-04-26
KR20200024111A (ko) 2020-03-06
PH12021550329A1 (en) 2021-10-04
SA521421262B1 (ar) 2024-02-29
DOP2021000030A (es) 2021-05-31
MA53507A (fr) 2022-04-27
AU2019331328A1 (en) 2021-03-11
CA3108856A1 (en) 2020-03-05
US12227498B2 (en) 2025-02-18
NZ772789A (en) 2024-09-27
BR122022001938B1 (pt) 2022-04-19
PE20251890A1 (es) 2025-07-25
CA3108856C (en) 2023-05-16
RU2760184C1 (ru) 2021-11-22

Similar Documents

Publication Publication Date Title
PE20210417A1 (es) Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
CN110072860B (zh) 可用作免疫调节剂的化合物
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
JP2025118762A (ja) ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
TWI875756B (zh) Ｃｄｋ抑制劑
PE20211411A1 (es) Compuestos de anillo fusionado
PE20231986A1 (es) Compuesto de heteroarilcarboxamida
EA021421B1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений
PE20240239A1 (es) Compuestos heterociclicos
US11345666B2 (en) Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
AR072809A1 (es) Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
AU2016361834A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
CL2024001922A1 (es) Compuesto de indazol y composición farmacéutica
US20250288683A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN103025722B (zh) 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性
US20250092032A1 (en) Deoxycytidine kinase inhibitors
AR047514A1 (es) Derivados de urea
US20230009323A1 (en) Compounds and methods for the treatment of cryptosporidiosis